CClinicalTrials.gg
RecruitingNCT05843890Updated Mar 9, 2026

Tailored Pain Guide (TPG) Study

An interventional study of Structured and tailored PainGuide and Standard PainGuide in Chronic Lower Back Pain, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This research is studying whether changing an individual's behaviors may have an impact as a treatment or outcome for chronic low back pain. This research will try to understand how much an electronic, self-management website like PainGuide can help participants.

The study hypothesizes that tailored digital interventions (plus using PainGuide) will demonstrate greater improvement in pain interference.

Read the detailed description

There was an amendment approved by the University of Michigan Medical School Institutional Review Board (AME00158411). This amendment included the following:

increased enrollment numbers, updated recruitment procedures including the Non-Pharma Program (NPP) Sub-Study, as well as changes in time frames.

02

Conditions studied

  • Chronic Lower Back Pain

Keywords

  • Online resources
  • Fitbit
  • Surveys
03

In context

Lead sponsor

University of Michigan is the lead sponsor of 1,475 studies on the registry; 196 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 128 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Chronic Lower Back pain (cLBP) defined by the National Institutes of Health (NIH) Task Force Report on Research Standards for Chronic Low Back Pain, (i.e., low back pain present at least six months, and present more than half of those days.)
  • Individuals must have a score of greater or equal to (≥) 60 on PROMIS Pain Interference.
  • Non-Pharma Sub-study:

    1. Must be referred and currently on the waitlist for the NPP at the Back \& Pain Center (BPC)

Exclusion criteria

Exclusion Criteria:

  • Current cancer related pain
  • Diagnosis of autoimmune disease
  • Unable to speak, write or read English
  • Visual or hearing difficulties
  • Pregnancy or breastfeeding
  • Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Structured and tailored PainGuide

    Behavioral: Structured and tailored PainGuide

  • Active comparator
    Standard PainGuide

    Behavioral: Standard PainGuide

Interventions

  • BehavioralStructured and tailored PainGuide

    Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2. The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks. The NPP Participants will be asked to complete surveys for 52 weeks. All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts).

  • BehavioralStandard PainGuide

    Participants in the control group will not receive any messaging once enrolled. The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks. The NPP Participants will be asked to complete surveys for 52 weeks. All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts).

06

What researchers measure

Primary outcomes

  1. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference score

    The PROMIS Pain Interference consists of 4-items that assess the degree to which pain interferes with various aspects of life. Items are scored on a 1 ("Not at all") to 5 ("Very much") scale with a range of 4 - 20. Higher scores indicate greater pain interference

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change in pain intensity based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There is one question that participants select 0 (no pain) - 10 (worst imaginable pain).

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  2. Change in the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive function

    There are 2 questions regarding cognitive function where participants select answers from not at all (1)-very mush (5) regarding cognitive function. There is a total of 10 points where higher scores mean higher cognitive function.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  3. Change in the physical function based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There are 4 questions that participants will select from without any difficulty (5) to unable to do (1). There are a total of 20 points where higher scores indicate higher physical function.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  4. Change in anxiety based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There are 4 questions that participants will select from never (1) to always (5). There are a total of 20 points where lower scores indicate lower levels of anxiety.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  5. Change in depression based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There are 4 questions that participants will select from never (1) to always (5). There are a total of 20 points where higher scores indicate higher levels of depression.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  6. Change in fatigue based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There are 4 questions that participants will select from not at all (1) to very much (5). There are a total of 20 points where higher scores indicate higher levels of fatigue.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  7. Change in sleep disturbance based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There are 4 questions that participants will select from. Question 1 participants will select from Very poor (5) to very good. Questions 2-4 participants will select from not all (5) to very much (1). There are a total of 20 points where higher scores indicate higher sleep disturbances.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  8. Change in ability to participate in social roles and activities based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There are 4 questions that participants will select from never (5) to always (1). There are a total of 20 points where lower scores indicate more difficulty participating in social roles.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  9. Change in pain interference based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0

    There are 4 questions that participants will select from not at all (1) to very much (5). There are a total of 20 points where lower scores indicate less pain interference.

    Time frame: Baseline, Week 24 (initial group), Week 52 (NPP group)

  10. Change in pain interference based on the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 version 2.0 - between baseline and 52 weeks for NPP participants

    There are 4 questions that participants will select from not at all (1) to very much (5). There are a total of 20 points where lower scores indicate less pain interference.

    Time frame: Baseline, Week 52 (T5)

07

Study locations

1 of 1 sites recruiting
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    • Beth Banner · Contact · eledward@umich.edu · 734-998-5837
    • Daniel Clauw, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843890
Lead sponsor
University of Michigan
Responsible party
Daniel Clauw, MD (Professor of Anesthesiology, University of Michigan) — Principal investigator
First posted
May 6, 2023
Start date
Aug 18, 2023
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Mar 9, 2026

Study contacts

Beth Banner
Contact
eledward@umich.edu
734-998-5837
Sana Shaikh
Contact
skazi@med.umich.edu
734-763-5226
Daniel Clauw, MD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion